Teriflunomide meets MS endpoint

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said teriflunomide met the primary endpoint of significantly reducing annualized relapse rate (ARR) from baseline to two years vs. placebo in a Phase III ...